The Surgeon General has issued an official “Call to Action” to reduce the number of cases of deep vein thrombosis and pulmonary embolism in the United States.
Deep vein thrombosis is a blood clot in a deep vein — most commonly in the lower leg or thigh — that can block blood flow and cause pain, swelling, and skin discoloration.
But it can turn deadly when deep vein thrombosis develops into pulmonary ...
continue reading...According to a report on ABC News, many first responders have mixed feelings about a decision to make cancer victims eligible for treatment and compensation under the World Trade Center Health Program.
The program set aside $4.3 billion to treat and otherwise compensate victims of the Sept. 11 terrorist attacks, including first responders who suffered health problems after inhaling toxic dust at the site of Ground Zero.
The fund previously included health problems including asthma, carpal tunnel syndrome and lower back pain. ...
continue reading...
The U.S. Food and Drug Administration intends to give priority review to Johnson & Johnson’s experimental treatment for multidrug-resistant tuberculosis.
According to a story in the Newark Star Ledger, Johnson & Johnson’s Janssen Research & Development unit applied for approval to market bedaquiline, or TMC207, on June 29. The drug would be included in combination therapy for adults with multidrug-resistant tuberculosis lung infections.
Under the FDA’s standard review process, the agency aims ...
continue reading...
Victims of the Sept. 11, 2001, terrorist attacks who were diagnosed with cancer after inhaling toxic dust will now be eligible for treatment under the World Trade Center Health Program, according to an ABC News report.
The program released a list of cancers now covered under the program, including mesothelioma – a type of cancer affecting the protective lining that covers many of the internal organs of the body called the ...
continue reading...
An article on investment blog Seeking Alpha highlights some recent problems facing pharmaceutical giant Eli Lilly, which potential investors might want to consider.
According to the blog, test results for a new schizophrenia drug proved disappointing. So much so that the company halted research into the product.
A new treatment for Alzheimer’s proved only partially effective against a mild form of the disease, and useless in most cases. A recent study also ...
continue reading...
According to Bloomberg, a Louisiana appeals court declined to throw out an award of nearly $258 million that Johnson & Johnson must pay to state officials, over illegal marketing of its antipsychotic drug Risperdal.
Jurors in Louisiana found Johnson & Johnson officials violated the state’s Medicaid fraud laws 35,542 times over Risperdal. Lawyers for the state argued that the company defrauded Louisiana’s Medicaid program by wrongfully marketing the drug to doctors ...
continue reading...
